In this study, defined cases of COVID-19 with mild, moderate or severe pneumonia will be treated with standard treatment regimens in combination with IV injection of Deferoxamine. Improvement in clinical, laboratory and radiological manifestations will be evaluated in treated patient compared to control group.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
50
Intravenous infusion of Deferoxamine
Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Kermanshah, Iran
RECRUITINGMortality rate
All cause of death
Time frame: up to 20 days
change in patients clinical manifestation
Mild, Moderate or Severe
Time frame: up to 20 days
change in patients PaO2
Time frame: up to 20 days
Length of hospitalization
days
Time frame: up to 20 days
C-reactive protein
Time frame: up to 20 days
lymphocyte count
Time frame: up to 20 days
length of intensive care unit stay
Time frame: 1 to 20 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.